Myocardial perfusion scintigraphy and 2-dimensional (2D) echocardiography are used for evaluating left ventricular function and ejection fraction (EF). This study aimed to validate the ...

Journal of Nuclear Medicine Technology June 2026, jnmt.125.271591; DOI: https://doi.org/10.2967/jnmt.125.271591 ...

Prostate-specific membrane antigen (PSMA) has fundamentally reshaped prostate cancer imaging and therapy, delivering an unprecedented combination of high lesion conspicuity, broad clinical ...

Prostate cancer is a rapidly expanding area for radiopharmaceutical therapy, primarily driven by prostate-specific membrane antigen–targeted imaging and therapy. This growth necessitates new workflows ...

Journal of Nuclear Medicine Technology October 2019, jnmt.119.231118; DOI: https://doi.org/10.2967/jnmt.119.231118 ...

Journal of Nuclear Medicine Technology April 2026, jnmt.125.271114; DOI: https://doi.org/10.2967/jnmt.125.271114 ...

Journal of Nuclear Medicine Technology April 2026, jnmt.126.272024; DOI: https://doi.org/10.2967/jnmt.126.272024 ...

Journal of Nuclear Medicine Technology April 2026, jnmt.126.272276; DOI: https://doi.org/10.2967/jnmt.126.272276 ...

Prostate cancer is one of the most prevalent malignancies in men and remains a leading cause of cancer-related morbidity and mortality worldwide. For many, prostate cancer follows an indolent course, ...

Journal of Nuclear Medicine Technology March 2026, jnmt.125.271050; DOI: https://doi.org/10.2967/jnmt.125.271050 ...

The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of ...